ClinicalTrials.gg
RecruitingNCT06029933Updated Aug 5, 2026

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

An observational study in Influenza, Community-acquired Pneumonia and Cardiovascular Events, sponsored by Kaiser Permanente. Recruiting at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Kaiser Permanente · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,500,000
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.

Planned enrollment
3rd of 122
1,500,000 · median 261
Started
2023
with 41 others
Observational
122 of 966
14 open now
Primary completion
2027-05
later than 34 of 83 live
Registered
862nd of 966
by date

Among the 966 studies in Influenza, Human with a site in United States, this one is the 3rd largest by planned enrollment of the 122 observational ones that give a count, is one of 42 that started in 2023, is one of 122 observational ones, reaches primary completion later than 34 of the 83 other live ones, and was the 862nd registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 966 studies in Influenza, Human with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24, 2024/25, and 2026/27 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.

03

Conditions studied

  • Influenza
  • Community-acquired Pneumonia
  • Cardiovascular Events
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study includes KPNC adults ≥65 years who receive Fluad or Fluzone High-Dose influenza vaccine as part of routine clinical care during the 2023/24, 2024/25, and/or 2026/27 influenza seasons.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥65 years at the time of influenza vaccination
  • KPNC member at the time of vaccination
  • Receive either aIIV4 or HD-IIV4 at a KPNC facility during the 2023/24 and/or 2024/25 influenza seasons

Exclusion criteria

Exclusion Criteria:

  • Age \<65 years at the time of influenza vaccination
  • Received either aIIV4 or HD-IIV4 in the inpatient setting
  • Receive more than one influenza vaccination during a single season period (i.e., 2023/24 or 2024/25 influenza seasons)
  • Receive an influenza vaccination outside of KPNC
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,500,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Fluad Recipients

    Kaiser Permanente Northern California members aged ≥65 years who receive Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)

    Biological: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)

  • Fluzone High-Dose Recipients

    Kaiser Permanente Northern California members aged ≥65 years who receive High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)

    Biological: High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)

Interventions

  • BiologicalAdjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)

    Fluad Quadrivalent vaccine is an inactivated influenza vaccine formulated to contain 60 mcg of hemagglutinin (HA) total, with 15 mcg from each of the four recommended influenza strains and the MF59 adjuvant in single-dose prefilled 0.5 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluad as part of routine clinical care during the influenza season.

    Also known as: Fluad

  • BiologicalHigh-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)

    Fluzone High-Dose Quadrivalent vaccine is an inactivated split virion influenza vaccine formulated to contain 240 mcg of HA total, with 60 mcg from each of the four recommended influenza strains in single-dose prefilled 0.7 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluzone High-Dose as part of routine clinical care during the influenza season.

    Also known as: Fluzone High-Dose

06

What researchers measure

Primary outcomes

  1. PCR-confirmed influenza

    KPNC members ≥65 years who receive Fluad or Fluzone High-Dose will be retrospectively assessed for the presence of PCR-confirmed influenza. This outcome will be assessed in single-season analyses (2023/24, 2024/25, and 2026/27 separately) and a pooled analysis across all seasons.

    Time frame: ≥14 days after vaccination until date of outcome, death, loss-to-follow-up, or end of each season (estimated May 2024, May 2025, or May 2027)

Secondary outcomes

  1. Emergency department visit or hospitalization for PCR-confirmed influenza

    KPNC members ≥65 years who receive Fluad or Fluzone High-Dose will be retrospectively assessed for an emergency department visit or hospitalization for PCR-confirmed influenza. This outcome will be assessed in single-season analyses (2023/24, 2024/25, and 2026/27 separately) and a pooled analysis across all seasons combined.

    Time frame: ≥14 days after vaccination until date of outcome, death, loss-to-follow-up, or end of each season (estimated May 2024, May 2025, or May 2027)

  2. Hospitalization for PCR-confirmed influenza

    KPNC members ≥65 years who receive Fluad or Fluzone High-Dose will be retrospectively assessed for hospitalization for PCR-confirmed influenza. This outcome will be assessed in a pooled analysis across all seasons combined.

    Time frame: ≥14 days after vaccination until date of outcome, death, loss-to-follow-up, or end of each season (estimated May 2024, May 2025, or May 2027)

  3. Hospitalization for all-cause community-acquired pneumonia

    KPNC members ≥65 years who receive Fluad or Fluzone High-Dose will be retrospectively assessed for hospitalization for all-cause community-acquired pneumonia. This outcome will be assessed in single-season analyses (2023/24, 2024/25, and 2026/27 separately) and a pooled analysis across all seasons combined.

    Time frame: ≥14 days after vaccination until date of outcome, death, loss-to-follow-up, or end of each season (estimated May 2024, May 2025, or May 2027)

Other outcomes

  1. Hospitalization for cardiovascular events

    KPNC members ≥65 years who receive Fluad or Fluzone High-Dose will be retrospectively assessed for hospitalization for cardiovascular events. This outcome will be assessed in single-season analyses (2023/24, 2024/25, and 2026/27 separately) and a pooled analysis across all seasons combined.

    Time frame: ≥14 days after vaccination until date of outcome, death, loss-to-follow-up, or end of each season (estimated May 2024, May 2025, or May 2027)

  2. PCR-confirmed influenza in subgroups with comorbidities

    KPNC members ≥65 years with comorbidities (e.g., cardiovascular and respiratory conditions, diabetes, obesity) who receive Fluad or Fluzone High-Dose will be retrospectively assessed for hospitalization for PCR-confirmed influenza. This outcome will be assessed in a pooled analysis across all seasons combined.

    Time frame: ≥14 days after vaccination until date of outcome, death, loss-to-follow-up, or end of each season (estimated May 2024, May 2025, or May 2027)

07

Study locations

1 of 1 sites recruiting
  • Kaiser Permanente Northern California (entire region)
    Oakland, California 94612, United States
    Recruiting
    • Amber H. Hyman, PhD, MPH · ContactAmber.Hyman@kp.org · (510) 267-7517
    • Nicola P. Klein, MD, PhD · Principal investigator
08

References and documents

Publications

  • Hsiao A, Leong T, Fireman B, Hansen J, Zerbo O, Jacobson KB, Liao LD, Haag MDM, McGovern I, Zhang B, Dang J, Klein NP. Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults: A Cluster Randomized Crossover Study. JAMA Netw Open. 2026 May 1;9(5):e2610120. doi: 10.1001/jamanetworkopen.2026.10120. PubMed 42081247 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for May 2027, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2023
First posted
Sep 8, 2023
StartActual
Aug 17, 2023
Primary completionEst.
May 2027
CompletionEst.
May 2028
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06029933
Lead sponsor
Kaiser Permanente
Collaborators
Seqirus
Responsible party
Sponsor
First posted
Sep 8, 2023
Start date
Aug 17, 2023
Primary completion
May 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Aug 5, 2026

Study contacts

Amber H. Hyman, PhD, MPH
Contact
Amber.Hyman@kp.org
510-267-7571

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion